Celiac disease screening: Difference between revisions
Jump to navigation
Jump to search
Usama Talib (talk | contribs) No edit summary |
m Bot: Removing from Primary care |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Screening with [[tissue transglutaminase]] (tTG) IgA test is recommended for symptomatic high risk patients. | Screening with [[tissue transglutaminase]] (tTG) IgA test is recommended for symptomatic high risk celiac disease patients. | ||
==Screening== | ==Screening== | ||
*Screening in asymptomatic | *Screening in asymptomatic celiac disease patients is not recommended.<ref name="pmid28350935">{{cite journal |vauthors=Chou R, Bougatsos C, Blazina I, Mackey K, Grusing S, Selph S |title=Screening for Celiac Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force |journal=JAMA |volume=317 |issue=12 |pages=1258–1268 |year=2017 |pmid=28350935 |doi=10.1001/jama.2016.10395 |url=}}</ref> | ||
*Screening is recommended for symptomatic and high risk patients with positive family history in first and second degree relatives | *Screening is recommended for symptomatic and high risk patients with positive family history in first and second degree relatives as well as in patients with other [[autoimmune diseases]] such as, [[Diabetes mellitus type 1|type 1 diabetes mellitus]], inflammatory luminal gastrointestinal disorders, [[Down syndrome]], [[Turner syndrome]], [[IgA deficiency]], and [[IgA nephropathy]].<ref name="pmid28350935">{{cite journal |vauthors=Chou R, Bougatsos C, Blazina I, Mackey K, Grusing S, Selph S |title=Screening for Celiac Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force |journal=JAMA |volume=317 |issue=12 |pages=1258–1268 |year=2017 |pmid=28350935 |doi=10.1001/jama.2016.10395 |url=}}</ref> | ||
*Screening method for celiac disease is tissue transglutaminase (tTG) IgA test. | *Screening method for celiac disease is tissue transglutaminase (tTG) IgA test. | ||
==References== | ==References== | ||
| Line 15: | Line 17: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
[[Category:Autoimmune diseases]] | [[Category:Autoimmune diseases]] | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Malnutrition]] | [[Category:Malnutrition]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
Latest revision as of 20:51, 29 July 2020
|
Celiac disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Medical Therapy |
|
Case Studies |
|
Celiac disease screening On the Web |
|
American Roentgen Ray Society Images of Celiac disease screening |
|
Risk calculators and risk factors for Celiac disease screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]
Overview
Screening with tissue transglutaminase (tTG) IgA test is recommended for symptomatic high risk celiac disease patients.
Screening
- Screening in asymptomatic celiac disease patients is not recommended.[1]
- Screening is recommended for symptomatic and high risk patients with positive family history in first and second degree relatives as well as in patients with other autoimmune diseases such as, type 1 diabetes mellitus, inflammatory luminal gastrointestinal disorders, Down syndrome, Turner syndrome, IgA deficiency, and IgA nephropathy.[1]
- Screening method for celiac disease is tissue transglutaminase (tTG) IgA test.